Dyne Therapeutics Names Editas Medicine's Lucera as CFO
Lucera, 57 years old, joins Dyne, a clinical-stage muscle disease company, from Editas Medicine, where he has served as CFO since May 2023, Dyne said Thursday. He has also held the top finance jobs at ...
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer
Proven financial leader brings decades of experience in capital allocation, business development and shareholder value creation -WALTHAM, ...
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced it ...